These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37004748)

  • 21.
    Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
    Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
    Bretonnière C; Boutoille D; Caillon J; Desessard C; Guitton C; Potel G; Jacqueline C
    Int J Antimicrob Agents; 2014 Sep; 44(3):218-21. PubMed ID: 25108877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
    Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
    J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 25. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
    Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO
    Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
    [No Abstract]   [Full Text] [Related]  

  • 27. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    Int J Antimicrob Agents; 2023 May; 61(5):106772. PubMed ID: 36878411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
    Gentry CA; Williams RJ
    Int J Antimicrob Agents; 2017 Mar; 49(3):333-338. PubMed ID: 28108367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
    Horikoshi Y; Higuchi H; Suwa J; Isogai M; Shoji T; Ito K
    J Infect Chemother; 2016 Aug; 22(8):532-5. PubMed ID: 27263807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
    Paul M; Yahav D; Bivas A; Fraser A; Leibovici L
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD005197. PubMed ID: 21069685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated Genome-Wide Analysis of an Isogenic Pair of
    Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
    Walkty A; Karlowsky JA; Adam H; Baxter M; Lagacé-Wiens P; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5707-9. PubMed ID: 23939895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
    Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.